Liver Fibrosis Drug-EMEA Market Status and Trend Report 2013-2023
Report Summary
Liver Fibrosis Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Liver Fibrosis Drug industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Liver Fibrosis Drug 2013-2017, and development forecast 2018-2023
Main market players of Liver Fibrosis Drug in EMEA, with company and product introduction, position in the Liver Fibrosis Drug market
Market status and development trend of Liver Fibrosis Drug by types and applications
Cost and profit status of Liver Fibrosis Drug, and marketing status
Market growth drivers and challenges
The report segments the EMEA Liver Fibrosis Drug market as:
EMEA Liver Fibrosis Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Liver Fibrosis Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Interferon
Maloti Lipid
Nucleoside
Other
EMEA Liver Fibrosis Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Research Center
Hospital
Clinic
EMEA Liver Fibrosis Drug Market: Players Segment Analysis (Company and Product introduction, Liver Fibrosis Drug Sales Volume, Revenue, Price and Gross Margin):
Bird Rock Bio, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Genfit SA
Gilead Sciences, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Dr. Falk Pharma GmbH
LG Life Science LTD.
Nitto Denko Corporation
Pfizer Inc.
Pharmaxis Limited
Promedior, Inc.
Dynavax Technologies Corporation
Evotec AG
FibroGen, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Liver Fibrosis Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Liver Fibrosis Drug industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Liver Fibrosis Drug 2013-2017, and development forecast 2018-2023
Main market players of Liver Fibrosis Drug in EMEA, with company and product introduction, position in the Liver Fibrosis Drug market
Market status and development trend of Liver Fibrosis Drug by types and applications
Cost and profit status of Liver Fibrosis Drug, and marketing status
Market growth drivers and challenges
The report segments the EMEA Liver Fibrosis Drug market as:
EMEA Liver Fibrosis Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Liver Fibrosis Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Interferon
Maloti Lipid
Nucleoside
Other
EMEA Liver Fibrosis Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Research Center
Hospital
Clinic
EMEA Liver Fibrosis Drug Market: Players Segment Analysis (Company and Product introduction, Liver Fibrosis Drug Sales Volume, Revenue, Price and Gross Margin):
Bird Rock Bio, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Genfit SA
Gilead Sciences, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Dr. Falk Pharma GmbH
LG Life Science LTD.
Nitto Denko Corporation
Pfizer Inc.
Pharmaxis Limited
Promedior, Inc.
Dynavax Technologies Corporation
Evotec AG
FibroGen, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF LIVER FIBROSIS DRUG
1.1 Definition of Liver Fibrosis Drug in This Report
1.2 Commercial Types of Liver Fibrosis Drug
1.2.1 Interferon
1.2.2 Maloti Lipid
1.2.3 Nucleoside
1.2.4 Other
1.3 Downstream Application of Liver Fibrosis Drug
1.3.1 Research Center
1.3.2 Hospital
1.3.3 Clinic
1.4 Development History of Liver Fibrosis Drug
1.5 Market Status and Trend of Liver Fibrosis Drug 2013-2023
1.5.1 EMEA Liver Fibrosis Drug Market Status and Trend 2013-2023
1.5.2 Regional Liver Fibrosis Drug Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Liver Fibrosis Drug in EMEA 2013-2017
2.2 Consumption Market of Liver Fibrosis Drug in EMEA by Regions
2.2.1 Consumption Volume of Liver Fibrosis Drug in EMEA by Regions
2.2.2 Revenue of Liver Fibrosis Drug in EMEA by Regions
2.3 Market Analysis of Liver Fibrosis Drug in EMEA by Regions
2.3.1 Market Analysis of Liver Fibrosis Drug in Europe 2013-2017
2.3.2 Market Analysis of Liver Fibrosis Drug in Middle East 2013-2017
2.3.3 Market Analysis of Liver Fibrosis Drug in Africa 2013-2017
2.4 Market Development Forecast of Liver Fibrosis Drug in EMEA 2018-2023
2.4.1 Market Development Forecast of Liver Fibrosis Drug in EMEA 2018-2023
2.4.2 Market Development Forecast of Liver Fibrosis Drug by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Liver Fibrosis Drug in EMEA by Types
3.1.2 Revenue of Liver Fibrosis Drug in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Liver Fibrosis Drug in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Liver Fibrosis Drug in EMEA by Downstream Industry
4.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Europe
4.2.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Middle East
4.2.3 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Africa
4.3 Market Forecast of Liver Fibrosis Drug in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVER FIBROSIS DRUG
5.1 EMEA Economy Situation and Trend Overview
5.2 Liver Fibrosis Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 LIVER FIBROSIS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Liver Fibrosis Drug in EMEA by Major Players
6.2 Revenue of Liver Fibrosis Drug in EMEA by Major Players
6.3 Basic Information of Liver Fibrosis Drug by Major Players
6.3.1 Headquarters Location and Established Time of Liver Fibrosis Drug Major Players
6.3.2 Employees and Revenue Level of Liver Fibrosis Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 LIVER FIBROSIS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Bird Rock Bio, Inc.
7.1.1 Company profile
7.1.2 Representative Liver Fibrosis Drug Product
7.1.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bird Rock Bio, Inc.
7.2 Bristol-Myers Squibb Company
7.2.1 Company profile
7.2.2 Representative Liver Fibrosis Drug Product
7.2.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
7.3 Celgene Corporation
7.3.1 Company profile
7.3.2 Representative Liver Fibrosis Drug Product
7.3.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.4 Dicerna Pharmaceuticals, Inc.
7.4.1 Company profile
7.4.2 Representative Liver Fibrosis Drug Product
7.4.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals, Inc.
7.5 Digna Biotech, S.L.
7.5.1 Company profile
7.5.2 Representative Liver Fibrosis Drug Product
7.5.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Digna Biotech, S.L.
7.6 Genfit SA
7.6.1 Company profile
7.6.2 Representative Liver Fibrosis Drug Product
7.6.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Genfit SA
7.7 Gilead Sciences, Inc.
7.7.1 Company profile
7.7.2 Representative Liver Fibrosis Drug Product
7.7.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences, Inc.
7.8 GNI Group Ltd.
7.8.1 Company profile
7.8.2 Representative Liver Fibrosis Drug Product
7.8.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of GNI Group Ltd.
7.9 HEC Pharm Co., Ltd.
7.9.1 Company profile
7.9.2 Representative Liver Fibrosis Drug Product
7.9.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of HEC Pharm Co., Ltd.
7.10 Dr. Falk Pharma GmbH
7.10.1 Company profile
7.10.2 Representative Liver Fibrosis Drug Product
7.10.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dr. Falk Pharma GmbH
7.11 LG Life Science LTD.
7.11.1 Company profile
7.11.2 Representative Liver Fibrosis Drug Product
7.11.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of LG Life Science LTD.
7.12 Nitto Denko Corporation
7.12.1 Company profile
7.12.2 Representative Liver Fibrosis Drug Product
7.12.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Nitto Denko Corporation
7.13 Pfizer Inc.
7.13.1 Company profile
7.13.2 Representative Liver Fibrosis Drug Product
7.13.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc.
7.14 Pharmaxis Limited
7.14.1 Company profile
7.14.2 Representative Liver Fibrosis Drug Product
7.14.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pharmaxis Limited
7.15 Promedior, Inc.
7.15.1 Company profile
7.15.2 Representative Liver Fibrosis Drug Product
7.15.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Promedior, Inc.
7.16 Dynavax Technologies Corporation
7.17 Evotec AG
7.18 FibroGen, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVER FIBROSIS DRUG
8.1 Industry Chain of Liver Fibrosis Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVER FIBROSIS DRUG
9.1 Cost Structure Analysis of Liver Fibrosis Drug
9.2 Raw Materials Cost Analysis of Liver Fibrosis Drug
9.3 Labor Cost Analysis of Liver Fibrosis Drug
9.4 Manufacturing Expenses Analysis of Liver Fibrosis Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVER FIBROSIS DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Liver Fibrosis Drug in This Report
1.2 Commercial Types of Liver Fibrosis Drug
1.2.1 Interferon
1.2.2 Maloti Lipid
1.2.3 Nucleoside
1.2.4 Other
1.3 Downstream Application of Liver Fibrosis Drug
1.3.1 Research Center
1.3.2 Hospital
1.3.3 Clinic
1.4 Development History of Liver Fibrosis Drug
1.5 Market Status and Trend of Liver Fibrosis Drug 2013-2023
1.5.1 EMEA Liver Fibrosis Drug Market Status and Trend 2013-2023
1.5.2 Regional Liver Fibrosis Drug Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Liver Fibrosis Drug in EMEA 2013-2017
2.2 Consumption Market of Liver Fibrosis Drug in EMEA by Regions
2.2.1 Consumption Volume of Liver Fibrosis Drug in EMEA by Regions
2.2.2 Revenue of Liver Fibrosis Drug in EMEA by Regions
2.3 Market Analysis of Liver Fibrosis Drug in EMEA by Regions
2.3.1 Market Analysis of Liver Fibrosis Drug in Europe 2013-2017
2.3.2 Market Analysis of Liver Fibrosis Drug in Middle East 2013-2017
2.3.3 Market Analysis of Liver Fibrosis Drug in Africa 2013-2017
2.4 Market Development Forecast of Liver Fibrosis Drug in EMEA 2018-2023
2.4.1 Market Development Forecast of Liver Fibrosis Drug in EMEA 2018-2023
2.4.2 Market Development Forecast of Liver Fibrosis Drug by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Liver Fibrosis Drug in EMEA by Types
3.1.2 Revenue of Liver Fibrosis Drug in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Liver Fibrosis Drug in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Liver Fibrosis Drug in EMEA by Downstream Industry
4.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Europe
4.2.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Middle East
4.2.3 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Africa
4.3 Market Forecast of Liver Fibrosis Drug in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVER FIBROSIS DRUG
5.1 EMEA Economy Situation and Trend Overview
5.2 Liver Fibrosis Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 LIVER FIBROSIS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Liver Fibrosis Drug in EMEA by Major Players
6.2 Revenue of Liver Fibrosis Drug in EMEA by Major Players
6.3 Basic Information of Liver Fibrosis Drug by Major Players
6.3.1 Headquarters Location and Established Time of Liver Fibrosis Drug Major Players
6.3.2 Employees and Revenue Level of Liver Fibrosis Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 LIVER FIBROSIS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Bird Rock Bio, Inc.
7.1.1 Company profile
7.1.2 Representative Liver Fibrosis Drug Product
7.1.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bird Rock Bio, Inc.
7.2 Bristol-Myers Squibb Company
7.2.1 Company profile
7.2.2 Representative Liver Fibrosis Drug Product
7.2.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
7.3 Celgene Corporation
7.3.1 Company profile
7.3.2 Representative Liver Fibrosis Drug Product
7.3.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.4 Dicerna Pharmaceuticals, Inc.
7.4.1 Company profile
7.4.2 Representative Liver Fibrosis Drug Product
7.4.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals, Inc.
7.5 Digna Biotech, S.L.
7.5.1 Company profile
7.5.2 Representative Liver Fibrosis Drug Product
7.5.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Digna Biotech, S.L.
7.6 Genfit SA
7.6.1 Company profile
7.6.2 Representative Liver Fibrosis Drug Product
7.6.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Genfit SA
7.7 Gilead Sciences, Inc.
7.7.1 Company profile
7.7.2 Representative Liver Fibrosis Drug Product
7.7.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences, Inc.
7.8 GNI Group Ltd.
7.8.1 Company profile
7.8.2 Representative Liver Fibrosis Drug Product
7.8.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of GNI Group Ltd.
7.9 HEC Pharm Co., Ltd.
7.9.1 Company profile
7.9.2 Representative Liver Fibrosis Drug Product
7.9.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of HEC Pharm Co., Ltd.
7.10 Dr. Falk Pharma GmbH
7.10.1 Company profile
7.10.2 Representative Liver Fibrosis Drug Product
7.10.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dr. Falk Pharma GmbH
7.11 LG Life Science LTD.
7.11.1 Company profile
7.11.2 Representative Liver Fibrosis Drug Product
7.11.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of LG Life Science LTD.
7.12 Nitto Denko Corporation
7.12.1 Company profile
7.12.2 Representative Liver Fibrosis Drug Product
7.12.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Nitto Denko Corporation
7.13 Pfizer Inc.
7.13.1 Company profile
7.13.2 Representative Liver Fibrosis Drug Product
7.13.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc.
7.14 Pharmaxis Limited
7.14.1 Company profile
7.14.2 Representative Liver Fibrosis Drug Product
7.14.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pharmaxis Limited
7.15 Promedior, Inc.
7.15.1 Company profile
7.15.2 Representative Liver Fibrosis Drug Product
7.15.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Promedior, Inc.
7.16 Dynavax Technologies Corporation
7.17 Evotec AG
7.18 FibroGen, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVER FIBROSIS DRUG
8.1 Industry Chain of Liver Fibrosis Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVER FIBROSIS DRUG
9.1 Cost Structure Analysis of Liver Fibrosis Drug
9.2 Raw Materials Cost Analysis of Liver Fibrosis Drug
9.3 Labor Cost Analysis of Liver Fibrosis Drug
9.4 Manufacturing Expenses Analysis of Liver Fibrosis Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVER FIBROSIS DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
